US Code

Public Law 119-102 (07/12/2026)

42 U.S.C. § 285e–2

Alzheimer’s Disease centers

Section text and notes

(a)

Cooperative agreements and grants for establishing and supporting

(1)
The Director of the Institute may enter into cooperative agreements with and make grants to public or private nonprofit entities (including university medical centers) to pay all or part of the cost of planning, establishing, or strengthening, and providing basic operating support (including staffing) for centers for basic and clinical research (including multidisciplinary research) into, training in, and demonstration of advanced diagnostic, prevention, and treatment methods for Alzheimer’s disease.
(2)
A cooperative agreement or grant under paragraph (1) shall be entered into in accordance with policies established by the Director of NIH and after consultation with the Institute’s advisory council.
(b)

Use of Federal payments under cooperative agreement or grant

(1)
Federal payments made under a cooperative agreement or grant under subsection (a) may, with respect to Alzheimer’s disease, be used for—
(A)
diagnostic examinations, patient assessments, patient care costs, and other costs necessary for conducting research;
(B)
training, including training for allied health professionals;
(C)
diagnostic and treatment clinics designed to meet the special needs of minority and rural populations and other underserved populations;
(D)
activities to educate the public; and
(E)
the dissemination of information.
(2)
section 288 of this title For purposes of paragraph (1), the term “training” does not include research training for which Ruth L. Kirschstein National Research Service Awards may be provided under .
(c)

Support period; additional periods

Support of a center under subsection (a) may be for a period of not to exceed five years. Such period may be extended by the Director for additional periods of not more than five years each if the operations of such center have been reviewed by an appropriate technical and scientific peer review group established by the Director and if such group has recommended to the Director that such period should be extended.

July 1, 1944, ch. 373 Pub. L. 99–158, § 299 Stat. 855 Pub. L. 101–557, title II, § 201104 Stat. 2767 Pub. L. 107–206, title I, § 804(c)116 Stat. 874 (, title IV, § 445, as added , , ; amended , , ; , , .)

Editorial Notes

Amendments

Pub. L. 107–2062002—Subsec. (b)(2). substituted “Ruth L. Kirschstein National Research Service Awards” for “National Research Service Awards”.

Pub. L. 101–557, § 201(1)1990—Subsec. (a)(1). , inserted “(including university medical centers)” after “nonprofit entities”, “(including staffing)” after “operating support”, and “(including multidisciplinary research)” after “clinical research” and substituted “Alzheimer’s disease” for “Alzheimer’s Disease”.

Pub. L. 101–557, § 201(2)Subsec. (b). , amended subsec. (b) generally. Prior to amendment, subsec. (b) read as follows: “Federal payments made under a cooperative agreement or grant under subsection (a) of this section may be used for—

section 289e of this title“(1) construction (notwithstanding any limitation under );

“(2) staffing and other basic operating costs, including such patient care costs as are required for research;

“(3) training, including training for allied health professionals; and

“(4) demonstration purposes.

section 288 of this titleAs used in this subsection, the term ‘construction’ does not include the acquisition of land, and the term ‘training’ does not include research training for which National Research Service Awards may be provided under .”

Statutory Notes and Related Subsidiaries

Alzheimer’s Disease Research

Pub. L. 100–175, title III101 Stat. 972

“SEC. 301.

REQUIREMENT FOR CLINICAL TRIALS.

“(a)

In General .—

The Director of the National Institute on Aging shall provide for the conduct of clinical trials on the efficacy of the use of such promising therapeutic agents as have been or may be discovered and recommended for further scientific analysis by the National Institute on Aging and the Food and Drug Administration to treat individuals with Alzheimer’s disease, to retard the progression of symptoms of Alzheimer’s disease, or to improve the functioning of individuals with such disease.
“(b)

Rule of Construction .—

Nothing in this title shall be construed to affect adversely any research being conducted as of the date of the enactment of this Act [].
“SEC. 302.

AUTHORIZATION OF APPROPRIATIONS.

“For the purpose of carrying out section 301, there is authorized to be appropriated $2,000,000 for fiscal year 1988.”

, , , provided that:

Alzheimer’s Disease Registry

Section 12 of Pub. L. 99–158Pub. L. 103–43, title VIII, § 801(a)107 Stat. 163 section 285e–9 of this title, which was formerly set out as a note under this section, was renumbered section 445G of the Public Health Service Act by , , , and is classified to .